The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
Americans with a chronic disease could soon have better access to affordable treatment if a bipartisan bill just passed by the U.S. House makes it through ...
The prevalence of fatigue among patients with chronic obstructive pulmonary disease (COPD) worldwide is approximately 59%, according to systematic review and meta-analysis findings published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback